Stifel Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $127
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha maintains a Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $124 to $127.
May 31, 2024 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Dae Gon Ha maintains a Buy rating on Ultragenyx Pharmaceutical and raises the price target from $124 to $127.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100